Clonal germinal center B cells function as a niche for T-cell lymphoma.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
03 11 2022
Historique:
accepted: 13 07 2022
received: 07 01 2022
pubmed: 4 8 2022
medline: 8 11 2022
entrez: 3 8 2022
Statut: ppublish

Résumé

Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes the development of T follicular helper (TFH)-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development using mouse models and human samples. Among the 2 mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre × Tet2flox/flox × G17V RHOA transgenic mice) spontaneously developed AITL for approximately up to a year, while mice lacking Tet2 only in the T cells (Cd4-Cre × Tet2flox/flox × G17V RHOA transgenic mice) did not. Therefore, Tet2-deficient immune cells function as a niche for AITL development. Single-cell RNA-sequencing (scRNA-seq) of >50 000 cells from mouse and human AITL samples revealed significant expansion of aberrant B cells, exhibiting properties of activating light zone (LZ)-like and proliferative dark zone (DZ)-like germinal center B (GCB) cells. The GCB cells in AITL clonally evolved with recurrent mutations in genes related to core histones. In silico network analysis using scRNA-seq data identified Cd40-Cd40lg as a possible mediator of GCB and tumor cell cluster interactions. Treatment of AITL model mice with anti-Cd40lg inhibitory antibody prolonged survival. The genes expressed in aberrantly expanded GCB cells in murine tumors were also broadly expressed in the B-lineage cells of TET2-mutant human AITL. Therefore, ACH-derived GCB cells could undergo independent clonal evolution and support the tumorigenesis in AITL via the CD40-CD40LG axis.

Identifiants

pubmed: 35921527
pii: S0006-4971(22)00975-2
doi: 10.1182/blood.2022015451
pmc: PMC10653021
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1937-1950

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Références

Science. 2014 Aug 29;345(6200):1058-62
pubmed: 25170154
J Exp Med. 2020 Oct 5;217(10):
pubmed: 32603407
Cell Stem Cell. 2017 Sep 7;21(3):374-382.e4
pubmed: 28803919
Cancer Sci. 2021 Dec;112(12):4931-4943
pubmed: 34657351
Br J Haematol. 2010 Mar;148(5):673-89
pubmed: 19961485
Blood. 1992 Apr 1;79(7):1789-95
pubmed: 1373088
Br J Haematol. 2007 Jul;138(1):44-53
pubmed: 17555446
Immunity. 2013 May 23;38(5):918-29
pubmed: 23684984
Immunity. 2001 Nov;15(5):763-74
pubmed: 11728338
Immunity. 2016 Jan 19;44(1):194-206
pubmed: 26795250
Nature. 2018 Nov;563(7731):347-353
pubmed: 30429548
Nat Genet. 2014 Feb;46(2):166-70
pubmed: 24413734
Haematologica. 2012 Oct;97(10):1594-602
pubmed: 22371178
Nature. 2021 Jan;589(7841):299-305
pubmed: 33299181
Nature. 2015 Jan 8;517(7533):214-8
pubmed: 25317561
Nat Methods. 2015 May;12(5):380-1
pubmed: 25924071
Nat Genet. 2014 Feb;46(2):171-5
pubmed: 24413737
Science. 2007 Jan 26;315(5811):528-31
pubmed: 17185562
Blood Cancer J. 2017 Jan 6;7(1):e516
pubmed: 28157189
Cancer Discov. 2018 Dec;8(12):1632-1653
pubmed: 30274972
Science. 1995 Sep 8;269(5229):1427-9
pubmed: 7660125
Blood Adv. 2020 Mar 10;4(5):868-879
pubmed: 32130407
Nature. 2021 Mar;591(7850):458-463
pubmed: 33536617
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Nat Commun. 2017 May 05;8:15081
pubmed: 28474673
Cell. 2017 Oct 5;171(2):481-494.e15
pubmed: 28985567
Blood. 2007 Jun 1;109(11):4952-63
pubmed: 17284527
Immunity. 2017 Aug 15;47(2):284-297.e5
pubmed: 28813659
Cancer Cell. 2011 Jul 12;20(1):25-38
pubmed: 21723201
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Nat Biotechnol. 2014 Apr;32(4):381-386
pubmed: 24658644
Leukemia. 2022 Jan;36(1):165-176
pubmed: 34230608
Cancer Res. 2020 May 1;80(9):1875-1884
pubmed: 32107212
J Exp Med. 2001 Oct 1;194(7):927-40
pubmed: 11581315
PLoS One. 2013 Jun 25;8(6):e64536
pubmed: 23825522
N Engl J Med. 2014 Dec 25;371(26):2488-98
pubmed: 25426837
Leukemia. 2018 Mar;32(3):694-702
pubmed: 28832024
Nature. 2021 Apr;592(7852):133-137
pubmed: 33597749

Auteurs

Manabu Fujisawa (M)

Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Tran B Nguyen (TB)

Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Yoshiaki Abe (Y)

Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan.

Yasuhito Suehara (Y)

Department of Hematology, University of Tsukuba Hospital, University of Tsukuba, Tsukuba, Japan.

Kota Fukumoto (K)

Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Department of Hematology, University of Tsukuba Hospital, University of Tsukuba, Tsukuba, Japan.

Sakurako Suma (S)

Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan.

Kenichi Makishima (K)

Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan.

Chihiro Kaneko (C)

Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Yen T M Nguyen (YTM)

Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Kensuke Usuki (K)

Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.

Kentaro Narita (K)

Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Japan.

Kosei Matsue (K)

Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Japan.

Naoya Nakamura (N)

Department of Pathology, Tokai University School of Medicine, Isehara, Japan.

Shumpei Ishikawa (S)

Department of Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Fumihito Miura (F)

Department of Biochemistry, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.

Takashi Ito (T)

Department of Biochemistry, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.

Ayako Suzuki (A)

Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan.

Yutaka Suzuki (Y)

Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan.

Seiya Mizuno (S)

Laboratory Animal Resource Center, University of Tsukuba, Tsukuba, Japan.

Satoru Takahashi (S)

Laboratory Animal Resource Center, University of Tsukuba, Tsukuba, Japan.

Shigeru Chiba (S)

Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Department of Hematology, University of Tsukuba Hospital, University of Tsukuba, Tsukuba, Japan.

Mamiko Sakata-Yanagimoto (M)

Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Department of Hematology, University of Tsukuba Hospital, University of Tsukuba, Tsukuba, Japan.
Division of Advanced Hemato-Oncology, Transborder Medical Research Center, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH